The Oncology InstituteTOIIW 62 Debt-to-Equity is -6.44 as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 62/100. The stock has 6 warning signs investors should review. Among 556 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 179855.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for The Oncology Institute's Debt-to-Equity or its related term are showing as below:
TOIIW'
s Debt-to-Equity Range Over the Past 10 Years
Min: -11.48 Med: 0.85 Max: 34.31
Current: -6.44
During the past 8 years, the highest Debt-to-Equity Ratio of The Oncology Institute was 34.31. The lowest was -11.48. And the median was 0.85.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
The Oncology Institute Debt-to-Equity Related Terms
The Oncology Institute Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOIIW vs CYH, SRTA, CCRN: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOIIW) has a Debt-to-Equity of -6.44 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #999999 out of 556 companies in the Healthcare Providers & Services industry.
Is The Oncology Institute's Debt-to-Equity too high?
The Oncology Institute's current Debt-to-Equity is -6.44. Based on the distribution chart, The Oncology Institute ranks #999999 out of 556 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Debt-to-Equity compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #999999 out of 556 companies for Debt-to-Equity. This places The Oncology Institute in the lower half of its industry. The industry median Debt-to-Equity is 0.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.40, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Debt-to-Equity is -6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Debt-to-Equity of -6.44. The current Debt-to-Equity is -6.44. The Oncology Institute's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Debt-to-Equity is -6.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
62GF Score
Get the complete analysis for TOIIW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
